Metastasis is the predominant cause of death from cancer yet we have few biomarkers to predict patients at increased risk of metastasis and are unable to effectively treat disseminated disease. Analysis of 448 primary breast tumors determined that expression of the hylauronan receptor CD44 associated with high grade (p = 0.046), ER- (p = 0.001) and PR-negative tumors (p = 0.029), and correlated with increased distant recurrence and reduced disease-free survival in patients with lymph-node positive or large tumors. To determine its functional role in distant metastasis, CD44 was knocked-down in MDA-MB-231 cells using two independent shRNA sequences. Loss of CD44 attenuated tumor cell adhesion to endothelial cells and reduced cell invasion but did not affect proliferation in vitro. To verify the importance of CD44 to post-intravasation events, tumor formation was assessed by quantitative in vivo imaging and post-mortem tissue analysis following an intra-cardiac injection of transfected cells. CD44 knock-down increased survival and decreased overall tumor burden at multiple sites, including the skeleton in vivo. We conclude that elevated CD44 expression on tumour cells within the systemic circulation increases the efficiency of post-intravasation events and distant metastasis in vivo, consistent with its association with increased distant recurrence and reduced disease-free survival in patients.
CD44 increases the efficiency of distant metastasis of breast cancer.
CD44 可提高乳腺癌远处转移的效率
阅读:3
作者:McFarlane Suzanne, Coulter Jonathan A, Tibbits Paul, O'Grady Anthony, McFarlane Cheryl, Montgomery Nicola, Hill Ashleigh, McCarthy Helen O, Young Leonie S, Kay Elaine W, Isacke Clare M, Waugh David J J
| 期刊: | Oncotarget | 影响因子: | 0.000 |
| 时间: | 2015 | 起止号: | 2015 May 10; 6(13):11465-76 |
| doi: | 10.18632/oncotarget.3410 | 靶点: | CD44 |
| 研究方向: | 肿瘤 | 疾病类型: | 乳腺癌 |
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
